As we navigate the modern era, the intersection of time-honoured natural remedies and contemporary scientific approaches forms a burgeoning frontier in global healthcare. For generations, natural products have been foundational to health solutions, serving as the primary healthcare choice for 80% to 85% of the world's population. These herbal-based, nature-derived substances, significant across diverse geographies, necessitate a renewed emphasis on enhancing their quality, efficacy, and safety. In the current century, the advent of biogenic phytonanoparticles has emerged as an innovative therapeutic conduit, perfectly aligning with principles of environmental safety and scientific ingenuity. Utilizing green chemistry techniques, a spectrum of metallic nanoparticles including elements such as copper, silver, iron, zinc, and titanium oxide can be produced with attributes of non-toxicity, sustainability, and economic efficiency. Sophisticated herb-mediated processes yield an array of plant-originated nanomaterials, each demonstrating unique physical, chemical, and biological characteristics. These attributes herald new therapeutic potentials, encompassing antioxidants, anti-aging applications, and more. Modern technology further accelerates the synthesis of natural products within laboratory settings, providing an efficient alternative to conventional isolation methods. The collaboration between traditional wisdom and advanced methodologies now signals a new epoch in healthcare. Here, the augmentation of traditional medicine is realized through rigorous scientific examination. By intertwining ethical considerations, cutting-edge technology, and natural philosophy, the realms of biogenic phytonanoparticles and traditional medicine forge promising pathways for research, development, and healing. The narrative of this seamless integration marks an exciting evolution in healthcare, where the fusion of sustainability and innovation crafts a future filled with endless possibilities for human well-being. The research in the development of metallic nanoparticles is crucial for unlocking their potential in revolutionizing fields such as medicine, catalysis, and electronics, promising groundbreaking applications with enhanced efficiency and tailored functionalities in future technologies. This exploration is essential for harnessing the unique properties of metallic nanoparticles to address pressing challenges and advance innovations across diverse scientific and industrial domains.

The global rise of antibiotic resistance (AR) presents a critical threat to public health, prompting the search for innovative antimicrobial strategies. Quorum sensing (QS), a bacterial communication system that governs virulence, biofilm formation, and resistance, has emerged as a compelling non-lethal therapeutic target. This review explores the potential of natural product-based quorum sensing inhibitors (QSIs) derived from plants, microbes, and marine organisms. These compounds disrupt QS pathways through various mechanisms, including inhibition of signal synthesis, receptor antagonism, enzymatic degradation of signaling molecules, and suppression of QS-regulated gene expression. Particular emphasis is placed on the molecular targets and synergistic potential of natural QSIs when combined with conventional antibiotics to enhance efficacy and curb resistance development. This narrative review explores the diverse sources of natural QSIs, including plant-derived phytochemicals, microbial secondary metabolites, and marine bioactive compounds. In this study, a thorough literature search was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. Studies selected were those published between 2013 and 2025 in peer-reviewed journals. The manuscript also examines translational challenges such as poor bioavailability, bacterial adaptability, and regulatory barriers, alongside innovative strategies including nanoparticle-based delivery and combination therapies. Finally, clinical and industrial applications of QSIs are discussed, reinforcing their promise as sustainable tools for combating resistant infections and biofilm-associated diseases. This review underscores QS inhibition as a transformative approach in the ongoing battle against antibiotic resistance.

Obesity is a major global health challenge, contributing to metabolic disorders such as type 2 diabetes, cardiovascular diseases, and hypertension. The increasing prevalence of obesity, driven by sedentary lifestyles, poor dietary habits, and genetic predisposition, underscores the urgent need for effective therapeutic strategies. Conventional pharmacological treatments, including appetite suppressants and metabolic modulators, often fail to provide sustainable weight loss due to side effects, poor adherence, and limited long-term efficacy. As a result, natural bioactive compounds have gained attention for their anti-obesity potential. However, their clinical application is hindered by poor bioavailability, rapid metabolism, and inefficient delivery. Lipid-based nano-carriers, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, offer a promising solution by enhancing the solubility, stability, and targeted delivery of these compounds. These advanced delivery systems improve bioactive retention, enable controlled release, and enhance therapeutic action on adipose tissue and metabolic pathways. Additionally, functionalized and stimulus-responsive nanocarriers present innovative approaches for precision obesity treatment. Despite these advancements, challenges remain in large-scale production, regulatory approval, and long-term safety. Overcoming these barriers is critical to ensuring the successful clinical translation of nano-formulated therapies. This review explores the potential of lipid-based nano-carriers in optimizing the therapeutic efficacy of natural anti-obesity compounds and highlights their role in advancing next-generation obesity management strategies. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds (created in https://BioRender.com )

Background: Cellular senescence is a fundamental characteristic of aging, marked by permanent cell cycle cessation and the release of pro-inflammatory mediators. Although senescence plays advantageous roles in tissue regeneration and tumor suppression, its accumulation leads to aging-related illnesses and functional deterioration. Objective: This review examines the processes of cellular senescence, its effects on aging and age-related disorders, and emerging therapeutic strategies to modulate senescence for promoting healthy aging. Methods: A thorough literature review was performed using peer-reviewed studies on cellular senescence, its molecular pathways, and therapeutic interventions. Emphasis was placed on senolytics, senomorphics, and lifestyle interventions that modulate senescence-associated pathways. Studies published in Scopus, Web of Science and PubMed between 2014– 2025 were selected. Results: Recent discoveries underscore the dual function of cellular senescence in aging and pathology. The senescence-associated secretory phenotype (SASP) fosters chronic inflammation and tissue dysfunction, connecting senescence to age-related diseases including cardiovascular conditions, dementia, and metabolic disorders. Therapeutic strategies, including senolytics (drugs that specifically eradicate senescent cells) and senomorphics (compounds that suppress SASP without killing cells), show promise in preclinical and clinical studies. Notably, dosing interals (intermittent vs continuous) influence both therapeutic efficacy and adverse events such as thrombocytopenia. Additionally, the state and limitations of clinical validation of aging biomarkers (eg, p16^INK4a, β-galactosidase) remain major hurdles for translation. Lifestyle interventions such as calorie restriction and exercise have also been identified as natural modulators of senescence pathways. Conclusion: Targeting cellular senescence offers a promising avenue for promoting healthy aging and mitigating age-linked diseases. Continued research into senescence-modulating interventions may lead to novel therapeutics designed to prolong healthspan and lifespan. Plain Language Summary: As we age, some of our cells stop dividing in a process called cellular senescence. These cells do not die, but instead release harmful substances that can cause inflammation and damage nearby healthy cells. While this process can be helpful early in life (like preventing cancer), too many of these cells in old age contribute to diseases such as heart problems, diabetes, and dementia. This study reviews recent research into ways to remove or control these “senescent” cells to support healthier aging. Two promising strategies are:Senolytics: drugs that kill senescent cells.Senomorphics: drugs that make senescent cells less harmful without killing them. Scientists are testing both types of drugs in animals and humans. Some natural compounds, like quercetin (found in apples and onions) and fisetin (found in strawberries), show potential benefits. Others like metformin and rapamycin, which are already used for diabetes or immune issues, might also help slow aging by targeting senescent cells. The study also emphasizes that healthy habits, like exercise and calorie restriction, naturally reduce the harmful effects of senescence. Despite promising results, challenges remain. We need more human studies to understand:Which treatments are safest and most effectiveHow to deliver them to the right parts of the bodyHow often they should be used The authors believe that combining senolytics, senomorphics, and lifestyle changes could significantly improve our health as we age.